{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:24:13Z","timestamp":1775039053035,"version":"3.50.1"},"posted":{"date-parts":[[2025,12,22]]},"group-title":"In Review","reference-count":2,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,12,4]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  <bold>Background<\/bold>\n                  Tuberculosis (TB) is a leading cause of morbidity and mortality around the world. TB treatment is complex and clinical research has focused on shortening duration. Understanding patient preferences around treatment shortening is an important field of study, especially is shorter regimens contain drugs that have side effects that are challenging for people receiving treatment. Clofazimine, a drug that can cause skin hyperpigmentation has been proposed as a component of shorter TB treatment regimens. Concerns about hyperpigmentation and its impact on disclosure have been raised as issues that could make such treatment unacceptable.\n                  <bold>Methods<\/bold>\n                  This was an exploratory, qualitative sub-study using in-depth interviews (IDIs) among purposively selected participants in the CLO-FAST trial (NCT04311502). CLO-FAST randomized participants to receive a standard, 6-month TB treatment regimen or a 3-month regimen containing clofazimine. A qualitative, exploratory sub-study of participants in the trial was undertaken to explore treatment preferences. Participants were asked about their experience with their assigned treatment regimen with a focus on disclosure of TB status and preferences for treatment. Data were analyzed by trained qualitative researchers using the theoretical framework of acceptability and the disclosure decision model.\n                  <bold>Results<\/bold>\n                  Twenty-three participants from India, Malawi and Zimbabwe were selected from the 89 participants in the parent trial. The major themes that were generated were: 1) decisions around deliberate disclosure; 2) experiences with inadvertent disclosure; 3) consequences of inadvertent disclosure; and 4) the impact of inadvertent disclosure on regimen preferences. Most participants expressed a preference for shorter regimen even if it led to skin color changes. Preferences for a longer regimen seemed to be driven by anticipated concerns around inadvertent disclosure and by a belief that longer regimens were more potent.\n                  <bold>Conclusions<\/bold>\n                  Preference assessment can be successfully built into therapeutic TB trials. Most participants prefer shorter treatment but concerns about potency and skin discoloration were expressed. Additional work is needed to delineate drivers of therapeutic preferences among people with TB.\n                  <bold>Trial Registration:<\/bold>\n                  NCT04311502, registered November 5, 2021.\n                <\/p>","DOI":"10.21203\/rs.3.rs-8277920\/v1","type":"posted-content","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T09:29:35Z","timestamp":1766395775000},"source":"Crossref","is-referenced-by-count":0,"title":["\u201cSix months is a lot of time to lie\u201d: Anticipated stigma, disclosure and treatment preferences among participants in a tuberculosis therapeutic trial"],"prefix":"10.21203","author":[{"given":"Faith","family":"Mugodhi","sequence":"first","affiliation":[{"name":"University of Zimbabwe-Clinical Trials Research Centre (UZ-CTRC)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Kanyama","sequence":"additional","affiliation":[{"name":"University of North Carolina Project"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Makiya","sequence":"additional","affiliation":[{"name":"Johns Hopkins Project, Blantyre Clinical Research Site"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Metcalfe","sequence":"additional","affiliation":[{"name":"University of California, San Francisco (UCSF)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charity","family":"Potani","sequence":"additional","affiliation":[{"name":"University of North Carolina Project"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly K.","family":"Scarsi","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Weir","sequence":"additional","affiliation":[{"name":"Harvard T.H. Chan School of Public Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Furin","sequence":"additional","affiliation":[{"name":"Harvard Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0001267","author":"Wingfield T","year":"2024","unstructured":"Global Tuberculosis Report 2024. Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024. Accessed November 24, 2024. 2World Health Organization, Wingfield T, Karmadwala F, Macpherson P, Global Burden of Diseases Study 2021, Bautista NSR, Nampewo E, Praygod Z, G., and, Wringe A, Strauss J, Wademan DT, Palmer M, Purchase S et al. Challenges and opportunities to end tuberculosis in the COVID-19 era. The Lancet Respiratory Medicine 2021, 9(6): 556-8. 3GBD 2021 Tuberculosis Collaborators. Global, regional, and national ag-specific progress towards the 2020 milestones of the WHO endTB strategy: a systematic analysis for the. The Lancet Infectious Diseases 2024. Available from https:\/\/www.thelancet.com\/journals\/laninf\/article\/PIIS1473-3099(24)00007-0\/fulltext. Accessed April 27, 2024. 4Naidoo, K., and Perumal, R. Advances in tuberculosis control in the past decade. The Lancet Respiratory Medicine 2023, 11(4). Available from: https:\/\/www.thelancet.com\/journals\/lanres\/article\/PIIS2213-2600(23)00090-5\/fulltext. Accessed April 27, 2024. 5 Ammerman, N., Swanson. R., Bautista, E., Impact of clofazimine dosing on treatment shortening of the first-line regimen in a mouse model of tuberculosis. Antimicrobial agents and chemotherapy 2018, 62(7): e00636-18. 6Gopal M, Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013;17(8): 1001\u20131007. 7Christodoulou, M. The stigma of tuberculosis. The Lancet Infectious Diseases 2011, 11(9): 663-4. 8Noguiera, A., Garcia, M., da Silva, M.,. Clofazimine-induced cutaneous hyperpigmentation as a source of stigma in the treatment of leprosy: A cross-sectional study. Tropical Medicine and International Health 2024, 29(4): 327\u2009\u2013\u200933. 9 Sanga, E., Nampewo, Z., Praygod, G., and Wringe, A. HIV positive status disclosure to sexual partners: a qualitative study to explore experiences and challenges among clients attending HIV care services in North-Western Tanzania. AIDS Care, 2023, 35:7, 953\u2013960. 0 Mdiba, S. and Josiah, U. Perceived Stigma and Fear of Unintended Disclosure are Barriers in Medication Adherence in Adolescents with Perinatal HIV in Botswana: A Qualitative Study. Biomed Research International, 2019, Article ID 9623159. 1 Corbin J, Strauss A. Basics of qualitative research: techniques and procedures for developing grounded theory. London: Sage; 2008. 12 Metcalfe, J., Weir, I., Scarsi, K.,. A 3-month clofazimine\u2013rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial. Lancet Infectious Diseases 2025, September 4. Available from: https:\/\/www.thelancet.com\/journals\/laninf\/article\/PIIS1473-3099%2825%2900436-0\/fulltext. Accessed November 17, 2025. 13 Wademan DT, Palmer M, Purchase S, Toward a conceptual framework of the acceptability of tuberculosis treatment in children using a theory generative approach. PLOS Global Public Health 2022, 2(12): e0001267. https:\/\/doi.org\/10.1371\/journal.pgph.0001267. 14 Omarzu, J. A disclosure decision model: Determining how and when individuals will self-disclose. Personality and Social Psychology Review, 2000, 4(2), 174\u2013185. 15 Salih MH, Mekonnen H, Derseh L, Lindgren H, Erlandsson K. Anticipated."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1371\/journal","author":"Nagarajan K","year":"2022","unstructured":"2022, 17(9): e0273734. 16 stigma and associated factors among chronic illness patients in Amhara Region Referral Hospitals, Ethiopia: A multicenter cross-sectional study. PLoS ONE, Nagarajan K, Muniyandi M, Sellappan S, Karunanidhi S, Senthilkumar K, Palani B, Perimal-Lewis L, Maeder AJ, Maartens G, Meintjes G, Wasserman S. A study on tuberculosis disease disclosure patterns and its associated factors: Findings from a prospective observational study in Chennai. PLoS One. 2023;18(1). https:\/\/doi.org\/10.1371\/journal.pone.0280812 17 Dormechele W, Bonsu EO, Boadi C,. Determinants of intention to conceal tuberculosis status among family members: an analysis of seven Sub-Saharan African countries. BMC Infect Dis. 2024;24:175. https:\/\/doi.org\/10.1186\/s12879-024-09064-y 18 Nezenega ZS, Perimal-Lewis L, Maeder AJ. Factors influencing patient adherence to tuberculosis treatment in Ethiopia: A literature review. Int J Environ Res Public Health. 2020;17(15):5626. https:\/\/doi.org\/10.3390\/ijerph17155626 19 Wademan DT, Draper HR, Purchase SE, Palmer M, Hesseling AC, van der Laan L, Garcia-Prats AJ. Acceptability of levofloxacin dispersible and non-dispersible tablet formulations in children receiving TB preventive treatment. IJTLD Open. 2024;1(2):69\u201375. doi: 10.5588\/ijtldopen.23.0462 20 Stadler JAM, Maartens G, Meintjes G, Wasserman S Clofazimine for the treatment of tuberculosis. Front Pharmacol. 2023;14:1100488. https:\/\/doi.org\/10.3389\/fphar.2023.1100488 21 Creswell, JW, Garrett, AL. The movement of mixed methods research and the role of educators. South African Journal of Education. 2008; 28(3): 321\u2013333. https:\/\/doi.org\/10.15700\/SAJE.V28N3A176."}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8277920\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8277920\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:14:38Z","timestamp":1775031278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8277920\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":2,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-8277920\/v1","relation":{},"subject":[],"published":{"date-parts":[[2025,12,22]]},"subtype":"preprint"}}